Kewaunee Scientific Reports 46.9% Increase in Q1 Sales and 61.3% Rise in Pre-Tax Earnings; EPS Climbs to $1.04

Reuters

09/11

Kewaunee Scientific Reports 46.9% Increase in Q1 Sales and 61.3% Rise in Pre-Tax Earnings; EPS Climbs to $1.04

Kewaunee Scientific Corporation announced its financial results for the first quarter of fiscal year 2026, which ended on July 31, 2025. The company reported sales of $71.1 million, marking a 46.9% increase compared to $48.4 million from the previous year's first quarter. Pre-tax earnings for the quarter rose by 61.3% to $3.92 million, up from $2.43 million in the prior year quarter. Net earnings were $3.1 million, an increase from $2.2 million in the same period last year. Diluted earnings per share were reported at $1.04, compared to $0.74 in the previous year quarter. Kewaunee's order backlog was reported to be $205.0 million as of July 31, 2025. Despite solid performance in the first quarter, Kewaunee anticipates uneven quarterly performance for the remainder of fiscal year 2026 due to volatility in project delivery timelines and challenging market conditions. The company is committed to strategic investments aimed at fostering both organic and inorganic growth, which are expected to impact near-term earnings growth but position the company for rapid and sustained growth in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kewaunee Scientific Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CL70866) on September 10, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2566842219"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566842219\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566842219?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-11 04:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566842219","market":"us","top_or_hot":-1,"title":"Kewaunee Scientific Reports 46.9% Increase in Q1 Sales and 61.3% Rise in Pre-Tax Earnings; EPS Climbs to $1.04","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kewaunee Scientific Reports 46.9% Increase in Q1 Sales and 61.3% Rise in Pre-Tax Earnings; EPS Climbs to $1.04\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kewaunee Scientific Corporation announced its financial results for the first quarter of fiscal year 2026, which ended on July 31, 2025. The company reported sales of $71.1 million, marking a 46.9% increase compared to $48.4 million from the previous year's first quarter. Pre-tax earnings for the quarter rose by 61.3% to $3.92 million, up from $2.43 million in the prior year quarter. Net earnings were $3.1 million, an increase from $2.2 million in the same period last year. Diluted earnings per share were reported at $1.04, compared to $0.74 in the previous year quarter. Kewaunee's order backlog was reported to be $205.0 million as of July 31, 2025. Despite solid performance in the first quarter, Kewaunee anticipates uneven quarterly performance for the remainder of fiscal year 2026 due to volatility in project delivery timelines and challenging market conditions. The company is committed to strategic investments aimed at fostering both organic and inorganic growth, which are expected to impact near-term earnings growth but position the company for rapid and sustained growth in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kewaunee Scientific Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CL70866) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kewaunee Scientific Reports 46.9% Increase in Q1 Sales and 61.3% Rise in Pre-Tax Earnings; EPS Climbs to $1.04</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKewaunee Scientific Reports 46.9% Increase in Q1 Sales and 61.3% Rise in Pre-Tax Earnings; EPS Climbs to $1.04\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-11 04:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kewaunee Scientific Reports 46.9% Increase in Q1 Sales and 61.3% Rise in Pre-Tax Earnings; EPS Climbs to $1.04\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kewaunee Scientific Corporation announced its financial results for the first quarter of fiscal year 2026, which ended on July 31, 2025. The company reported sales of $71.1 million, marking a 46.9% increase compared to $48.4 million from the previous year's first quarter. Pre-tax earnings for the quarter rose by 61.3% to $3.92 million, up from $2.43 million in the prior year quarter. Net earnings were $3.1 million, an increase from $2.2 million in the same period last year. Diluted earnings per share were reported at $1.04, compared to $0.74 in the previous year quarter. Kewaunee's order backlog was reported to be $205.0 million as of July 31, 2025. Despite solid performance in the first quarter, Kewaunee anticipates uneven quarterly performance for the remainder of fiscal year 2026 due to volatility in project delivery timelines and challenging market conditions. The company is committed to strategic investments aimed at fostering both organic and inorganic growth, which are expected to impact near-term earnings growth but position the company for rapid and sustained growth in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kewaunee Scientific Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CL70866) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KEQU","symbol_name":"基瓦尼科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL3KGXJt:1","article_id":"2566842219","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566842219","pubTimestamp":1757534917,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kewaunee Scientific Corporation announced its financial results for the first quarter of fiscal year 2026, which ended on July 31, 2025. The company reported sales of $71.1 million, marking a 46.9% increase compared to $48.4 million from the previous year's first quarter. Pre-tax earnings for the quarter rose by 61.3% to $3.92 million, up from $2.43 million in the prior year quarter. Net earnings were $3.1 million, an increase from $2.2 million in the same period last year. Diluted earnings per share were reported at $1.04, compared to $0.74 in the previous year quarter. Kewaunee's order backlog was reported to be $205.0 million as of July 31, 2025. Despite solid performance in the first quarter, Kewaunee anticipates uneven quarterly performance for the remainder of fiscal year 2026 due to volatility in project delivery timelines and challenging market conditions. The company is committed to strategic investments aimed at fostering both organic and inorganic growth, which are expected ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"KEQU":"基瓦尼科技"},"translate_title":"Kewaunee Scientific报告第一季度销售额增长46.9%，税前收益增长61.3%；每股收益攀升至1.04美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KEQU":0.9},"content_text":"Kewaunee Scientific Reports 46.9% Increase in Q1 Sales and 61.3% Rise in Pre-Tax Earnings; EPS Climbs to $1.04\n    \n\n        Kewaunee Scientific Corporation announced its financial results for the first quarter of fiscal year 2026, which ended on July 31, 2025. The company reported sales of $71.1 million, marking a 46.9% increase compared to $48.4 million from the previous year's first quarter. Pre-tax earnings for the quarter rose by 61.3% to $3.92 million, up from $2.43 million in the prior year quarter. Net earnings were $3.1 million, an increase from $2.2 million in the same period last year. Diluted earnings per share were reported at $1.04, compared to $0.74 in the previous year quarter. Kewaunee's order backlog was reported to be $205.0 million as of July 31, 2025. Despite solid performance in the first quarter, Kewaunee anticipates uneven quarterly performance for the remainder of fiscal year 2026 due to volatility in project delivery timelines and challenging market conditions. The company is committed to strategic investments aimed at fostering both organic and inorganic growth, which are expected to impact near-term earnings growth but position the company for rapid and sustained growth in the future.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kewaunee Scientific Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CL70866) on September 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}